CRSP
Price
$55.21
Change
-$1.50 (-2.65%)
Updated
Dec 26, 02:43 PM (EDT)
Capitalization
5.4B
53 days until earnings call
Intraday BUY SELL Signals
PRME
Price
$3.57
Change
-$0.12 (-3.25%)
Updated
Dec 24 closing price
Capitalization
644.42M
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs PRME

Header iconCRSP vs PRME Comparison
Open Charts CRSP vs PRMEBanner chart's image
CRISPR Therapeutics AG
Price$55.21
Change-$1.50 (-2.65%)
Volume$670
Capitalization5.4B
Prime Medicine
Price$3.57
Change-$0.12 (-3.25%)
Volume$2.29M
Capitalization644.42M
CRSP vs PRME Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. PRME commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and PRME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (CRSP: $56.71 vs. PRME: $3.57)
Brand notoriety: CRSP and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 30% vs. PRME: 58%
Market capitalization -- CRSP: $5.4B vs. PRME: $644.42M
CRSP [@Biotechnology] is valued at $5.4B. PRME’s [@Biotechnology] market capitalization is $644.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 4 bearish.
  • PRME’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than PRME.

Price Growth

CRSP (@Biotechnology) experienced а +3.60% price change this week, while PRME (@Biotechnology) price change was -4.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 17, 2026.

PRME is expected to report earnings on Feb 27, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.4B) has a higher market cap than PRME($644M). CRSP YTD gains are higher at: 44.080 vs. PRME (22.260). PRME has higher annual earnings (EBITDA): -196.8M vs. CRSP (-555.73M). CRSP has more cash in the bank: 1.92B vs. PRME (213M). PRME has less debt than CRSP: PRME (118M) vs CRSP (211M). CRSP has higher revenues than PRME: CRSP (35M) vs PRME (5.98M).
CRSPPRMECRSP / PRME
Capitalization5.4B644M839%
EBITDA-555.73M-196.8M282%
Gain YTD44.08022.260198%
P/E RatioN/AN/A-
Revenue35M5.98M586%
Total Cash1.92B213M900%
Total Debt211M118M179%
FUNDAMENTALS RATINGS
CRSP vs PRME: Fundamental Ratings
CRSP
PRME
OUTLOOK RATING
1..100
2279
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
4655
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
5031

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (41) in the null industry is in the same range as CRSP (72) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

CRSP's Price Growth Rating (46) in the Biotechnology industry is in the same range as PRME (55) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPPRME
RSI
ODDS (%)
Bullish Trend 3 days ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signal:
Gain/Loss:
PRME
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FHEAX16.520.12
+0.73%
Fidelity Advisor Real Estate A
SWDSX18.100.08
+0.44%
Schwab Dividend Equity
LAFVX20.590.07
+0.34%
Lord Abbett Affiliated R6
AEDMX15.140.04
+0.26%
American Century Emerging Markets R6
BALSX9.66N/A
N/A
BlackRock U.S. Insights Lon/Shr Eq Inv A

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.44%
BEAM - CRSP
71%
Closely correlated
+1.33%
RXRX - CRSP
67%
Closely correlated
+0.92%
ABSI - CRSP
61%
Loosely correlated
+1.14%
NTLA - CRSP
60%
Loosely correlated
+1.80%
PRME - CRSP
60%
Loosely correlated
-3.25%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-3.25%
CRSP - PRME
61%
Loosely correlated
+0.44%
BEAM - PRME
59%
Loosely correlated
+1.33%
RXRX - PRME
53%
Loosely correlated
+0.92%
EDIT - PRME
50%
Loosely correlated
+0.91%
ABCL - PRME
47%
Loosely correlated
+0.81%
More